Immunoprecise Antibodies Ltd (IPA)

$2.89 +0.32 (12.45%)
Market Cap 118.62M
Revenue (ttm) 17.59M
Net Income (ttm) -21.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -123.31%
Debt to Equity Ratio 0.00
Volume 1,651,800
Avg Vol 3,225,662
Day's Range N/A - N/A
Shares Out 46.15M
Stochastic %K 99%
Beta 0.49
Analysts Sell
Price Target $4.00

Company Profile

ImmunoPrecise Antibodies Ltd. operates as a AI-driven biotherapeutic research and technology company. It leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies; and support the discovery and development of therapeutic antibodies. The company's contract research organizations services include B cell Select platforms that enable antibody screening directly from B cells, facilitating the analysis of a set of antibodies, as well a...

Industry: Biotechnology
Sector: Healthcare
Phone: 603 8949 3199
Fax: 603 8949 3198
Address:
Jalan Prima Tropika Barat 2,, Lot 1 to 3 Taman Prima Tropika, Seri Kembangan, Malaysia
NyseDayTrader
NyseDayTrader Aug. 21 at 11:54 AM
$IPA This is only a 131 million dollar cap here.. Only higher
0 · Reply
Itradestocks999
Itradestocks999 Aug. 21 at 11:07 AM
$IPA Hopping into this today for a swing
0 · Reply
NyseDayTrader
NyseDayTrader Aug. 21 at 10:12 AM
$IPA give us fuel bath!
0 · Reply
NyseDayTrader
NyseDayTrader Aug. 21 at 9:30 AM
$IPA
0 · Reply
teddiskim
teddiskim Aug. 21 at 4:43 AM
$IPA is there anyone else here more excited than me for tomorrow?
1 · Reply
StockScanners
StockScanners Aug. 21 at 1:18 AM
$IPA reached 2.95, keep watch
0 · Reply
Stockgirl99
Stockgirl99 Aug. 20 at 10:40 PM
$IPA Well we did it! 🙌 (and I did mean 52-week high)!
0 · Reply
Uzurcoconut
Uzurcoconut Aug. 20 at 10:25 PM
$PLTR … let’s head to 200 $CRDF $IPA $VOR $SOFI
0 · Reply
Stockgirl99
Stockgirl99 Aug. 20 at 9:25 PM
$IPA Holding up very nicely - and then some! 📈
0 · Reply
DA98520
DA98520 Aug. 20 at 9:19 PM
$IPA decided to exercise some of my options early today. Wanted to add more while I still can for the long term. Waiting for other funds to settle to finish doubling my position.
0 · Reply
Latest News on IPA
AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

Aug 6, 2025, 8:00 AM EDT - 15 days ago

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

Aug 6, 2025, 8:00 AM EDT - 15 days ago

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript

Jul 29, 2025, 12:39 PM EDT - 22 days ago

ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

Jul 29, 2025, 8:28 AM EDT - 23 days ago

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

Jul 24, 2025, 8:22 AM EDT - 4 weeks ago

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

Jul 21, 2025, 8:28 AM EDT - 4 weeks ago

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

Jul 16, 2025, 8:05 AM EDT - 5 weeks ago

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 14, 2025, 8:01 AM EDT - 5 weeks ago

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

Jul 7, 2025, 9:00 AM EDT - 6 weeks ago

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

Jul 3, 2025, 8:19 AM EDT - 7 weeks ago

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

Jun 24, 2025, 7:02 AM EDT - 2 months ago

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

Jun 12, 2025, 8:01 AM EDT - 2 months ago

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

Jun 5, 2025, 8:01 AM EDT - 2 months ago

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

AMD

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

May 21, 2025, 8:49 AM EDT - 3 months ago

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

May 20, 2025, 8:28 AM EDT - 3 months ago

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

May 12, 2025, 8:01 AM EDT - 3 months ago

IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

AMD

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

Apr 11, 2025, 8:40 AM EDT - 4 months ago

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript

Mar 28, 2025, 12:59 PM EDT - 5 months ago

ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

Mar 28, 2025, 8:01 AM EDT - 5 months ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

Mar 13, 2025, 7:02 AM EDT - 5 months ago

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

Mar 11, 2025, 10:17 PM EDT - 5 months ago

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

Mar 5, 2025, 8:01 AM EST - 6 months ago

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

Feb 26, 2025, 8:01 AM EST - 6 months ago

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

ImmunoPrecise Antibodies Announces Key Leadership Changes

Feb 24, 2025, 8:01 AM EST - 6 months ago

ImmunoPrecise Antibodies Announces Key Leadership Changes

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

Feb 20, 2025, 8:01 AM EST - 6 months ago

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture

Jan 27, 2025, 8:01 AM EST - 7 months ago

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

Jan 22, 2025, 7:02 AM EST - 7 months ago

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

Jan 17, 2025, 8:01 AM EST - 7 months ago

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

IPA Announces Resignation of Chief Financial Officer

Dec 31, 2024, 7:56 PM EST - 8 months ago

IPA Announces Resignation of Chief Financial Officer

$116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors

Dec 30, 2024, 10:03 PM EST - 8 months ago

$116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors

MMI

ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases

Dec 23, 2024, 8:30 AM EST - 8 months ago

ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases

IPA to Present at The Microcap Conference 2025

Dec 19, 2024, 10:15 AM EST - 8 months ago

IPA to Present at The Microcap Conference 2025

ImmunoPrecise Antibodies Ltd. (IPA) Q2 2025 Earnings Call Transcript

Dec 10, 2024, 5:33 PM EST - 9 months ago

ImmunoPrecise Antibodies Ltd. (IPA) Q2 2025 Earnings Call Transcript

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025

Dec 10, 2024, 8:30 AM EST - 9 months ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025

IPA to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Dec 4, 2024, 8:00 AM EST - 9 months ago

IPA to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024

Dec 3, 2024, 8:30 AM EST - 9 months ago

IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies

Nov 13, 2024, 9:00 AM EST - 10 months ago

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies

ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation

Nov 4, 2024, 8:01 AM EST - 10 months ago

ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation

ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology

Oct 28, 2024, 7:30 AM EDT - 10 months ago

ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology

ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024

Oct 21, 2024, 9:00 AM EDT - 10 months ago

ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024

Institutional Property Advisors Brokers $92.5 Million Multifamily Sale in L.A.'s NoHo Arts District

Oct 16, 2024, 2:54 PM EDT - 11 months ago

Institutional Property Advisors Brokers $92.5 Million Multifamily Sale in L.A.'s NoHo Arts District

MMI

ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design

Oct 10, 2024, 8:10 AM EDT - 11 months ago

ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design

ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus

Oct 2, 2024, 8:00 AM EDT - 11 months ago

ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus

ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments

Sep 26, 2024, 9:00 AM EDT - 11 months ago

ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments

ImmunoPrecise Antibodies Ltd. (IPA) Q1 2025 Earnings Call Transcript

Sep 16, 2024, 1:46 PM EDT - 1 year ago

ImmunoPrecise Antibodies Ltd. (IPA) Q1 2025 Earnings Call Transcript

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025

Sep 16, 2024, 9:00 AM EDT - 1 year ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024

Sep 9, 2024, 9:11 AM EDT - 1 year ago

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

Aug 26, 2024, 9:00 AM EDT - 1 year ago

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements

Aug 23, 2024, 8:00 PM EDT - 1 year ago

ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements

ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology

Aug 19, 2024, 9:00 AM EDT - 1 year ago

ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology

NyseDayTrader
NyseDayTrader Aug. 21 at 11:54 AM
$IPA This is only a 131 million dollar cap here.. Only higher
0 · Reply
Itradestocks999
Itradestocks999 Aug. 21 at 11:07 AM
$IPA Hopping into this today for a swing
0 · Reply
NyseDayTrader
NyseDayTrader Aug. 21 at 10:12 AM
$IPA give us fuel bath!
0 · Reply
NyseDayTrader
NyseDayTrader Aug. 21 at 9:30 AM
$IPA
0 · Reply
teddiskim
teddiskim Aug. 21 at 4:43 AM
$IPA is there anyone else here more excited than me for tomorrow?
1 · Reply
StockScanners
StockScanners Aug. 21 at 1:18 AM
$IPA reached 2.95, keep watch
0 · Reply
Stockgirl99
Stockgirl99 Aug. 20 at 10:40 PM
$IPA Well we did it! 🙌 (and I did mean 52-week high)!
0 · Reply
Uzurcoconut
Uzurcoconut Aug. 20 at 10:25 PM
$PLTR … let’s head to 200 $CRDF $IPA $VOR $SOFI
0 · Reply
Stockgirl99
Stockgirl99 Aug. 20 at 9:25 PM
$IPA Holding up very nicely - and then some! 📈
0 · Reply
DA98520
DA98520 Aug. 20 at 9:19 PM
$IPA decided to exercise some of my options early today. Wanted to add more while I still can for the long term. Waiting for other funds to settle to finish doubling my position.
0 · Reply
NyseDayTrader
NyseDayTrader Aug. 20 at 9:08 PM
Current Recap Shares: 100,500 $IPA 10k $HTZ 3800 $SPXU 150 $SOL.X 7200 $GRRR & 100 1/15/27 calls
3 · Reply
kubota2323
kubota2323 Aug. 20 at 8:34 PM
$IPA https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=IPA Breakout watch 2.94
1 · Reply
kubota2323
kubota2323 Aug. 20 at 8:00 PM
$IPA excellent close.
0 · Reply
Stockgirl99
Stockgirl99 Aug. 20 at 7:25 PM
$IPA When do y’all think we’ll get news?
1 · Reply
teddiskim
teddiskim Aug. 20 at 7:24 PM
$IPA omg she’s gonna hit $3 before EOD
0 · Reply
NyseDayTrader
NyseDayTrader Aug. 20 at 7:22 PM
$IPA
0 · Reply
BigRig_Trader
BigRig_Trader Aug. 20 at 7:16 PM
$IPA I’m buying right now. Thought I was done but ……
1 · Reply
BigRig_Trader
BigRig_Trader Aug. 20 at 7:04 PM
$IPA https://x.com/bigrig_trader/status/1958243526199882071?s=46&t=HgNvzT8oCwyzz9Wr4YO4tA
0 · Reply
BigRig_Trader
BigRig_Trader Aug. 20 at 6:57 PM
$IPA if you think this is fun, wait till news flow starts after the rebrand news hits! This is inning one of a long AI game
0 · Reply
kubota2323
kubota2323 Aug. 20 at 6:54 PM
$IPA https://stockcharts.com/sc3/ui/?s=IPA&p=D&yr=0&mn=3&dy=0&id=p92585419785 Almost go time
0 · Reply
NyseDayTrader
NyseDayTrader Aug. 20 at 6:51 PM
$IPA This so wants to go
0 · Reply
Scam_Likely
Scam_Likely Aug. 20 at 6:46 PM
$IPA I have seen a ton of scams.. China hustle scams.. dilution machines.. EV bullshit.. Biotrash.. etc.. This is an exceptional opportunity. Anyone who has done the DD into the filings and history of this company can see how they have not only grown and adapted, they have only diluted in small responsible batches when absolutely necessary… They had the foresight to adopt AI and put It to work immediately. Cost effective, it gets more accurate the more you use it, and the more partners you have.. Nothing but upside potential and a responsible board of medical professionals.. not people who have made a career out of scamming investors.
0 · Reply